Pacific Biosciences Of California, Inc. PACB
We take great care to ensure that the data presented and summarized in this overview for PACIFIC BIOSCIENCES OF CALIFORNIA, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PACB
View all-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl33.4MShares$65.8 Million0.54% of portfolio
-
Black Rock Inc. New York, NY23.6MShares$46.5 Million0.0% of portfolio
-
Madrone Advisors, LLC Menlo Park, CA23.4MShares$46.1 Million6.35% of portfolio
-
Edmond De Rothschild Holding S.A. Chambesy, V820.3MShares$40 Million0.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA17.6MShares$34.8 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.11.9MShares$23.4 Million0.23% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.11.9MShares$23.4 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny10.4MShares$20.5 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA6.33MShares$12.5 Million0.0% of portfolio
-
Jackson Square Partners, LLC San Francisco, CA6.3MShares$12.4 Million0.93% of portfolio
Latest Institutional Activity in PACB
Top Purchases
Top Sells
About PACB
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Insider Transactions at PACB
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 30
2024
|
Susan G. Kim Officer |
SELL
Open market or private sale
|
Direct |
19,782
-2.77%
|
$19,782
$1.72 P/Share
|
Sep 16
2024
|
Christian O Henry Officer |
SELL
Open market or private sale
|
Direct |
98,907
-3.81%
|
$98,907
$1.75 P/Share
|
Aug 19
2024
|
Jeff Eidel Officer |
SELL
Open market or private sale
|
Direct |
26,760
-2.99%
|
$26,760
$1.59 P/Share
|
Aug 16
2024
|
Mark Van Oene Officer |
SELL
Open market or private sale
|
Direct |
38,011
-2.28%
|
$38,011
$1.66 P/Share
|
Jun 18
2024
|
Hannah Valantine Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,821
+50.0%
|
-
|
Jun 18
2024
|
Marshall Mohr Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,821
+14.66%
|
-
|
Jun 18
2024
|
Kathy Ordonez Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,821
+5.36%
|
-
|
Jun 18
2024
|
Lucy Shapiro Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,821
+50.0%
|
-
|
Jun 18
2024
|
David W Meline Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,116
+23.06%
|
-
|
Jun 18
2024
|
John F Milligan Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,821
+14.66%
|
-
|
Jun 18
2024
|
William W. Ericson Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,821
+35.42%
|
-
|
Jun 18
2024
|
Randall S Livingston Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,821
+50.0%
|
-
|
May 20
2024
|
Michele Farmer Officer |
SELL
Open market or private sale
|
Direct |
5,275
-2.43%
|
$10,550
$2.03 P/Share
|
Mar 15
2024
|
Kathy Ordonez Director |
BUY
Exercise of conversion of derivative security
|
Direct |
361,621
+28.75%
|
$723,242
$2.77 P/Share
|
Mar 06
2024
|
David W Meline Director |
BUY
Open market or private purchase
|
Direct |
40,000
+50.0%
|
$160,000
$4.4 P/Share
|
Mar 04
2024
|
Michele Farmer Officer |
SELL
Open market or private sale
|
Direct |
2,968
-1.35%
|
$11,872
$4.87 P/Share
|
Mar 04
2024
|
Mark Van Oene Officer |
SELL
Open market or private sale
|
Direct |
9,186
-0.55%
|
$36,744
$4.87 P/Share
|
Mar 04
2024
|
Susan G. Kim Officer |
SELL
Open market or private sale
|
Direct |
5,275
-0.74%
|
$21,100
$4.87 P/Share
|
Mar 04
2024
|
Christian O Henry Officer |
SELL
Open market or private sale
|
Direct |
14,177
-0.54%
|
$56,708
$4.87 P/Share
|
Mar 01
2024
|
Marshall Mohr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+18.52%
|
$100,000
$4.45 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 3.59M shares |
---|---|
Open market or private purchase | 40K shares |
Exercise of conversion of derivative security | 387K shares |
Open market or private sale | 412K shares |
---|